BioMarin to Announce Preliminary 2025 Financial Results at J.P. Morgan Conference on January 12
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: Newsfilter
- Conference Announcement: BioMarin Pharmaceutical's CEO Alexander Hardy will present at the 44th Annual J.P. Morgan Conference on January 12, 2026, at 11:15 AM PT, where the company is expected to announce preliminary financial results for the year ended December 31, 2025, enhancing investor interest in the company's future performance.
- Live Webcast: The presentation will be available via audio webcast, allowing investors to listen live through the company's website, which increases transparency and provides a direct information channel for potential investors.
- Company Background: Founded in 1997, BioMarin focuses on delivering innovative medicines for patients with rare diseases, boasting eight commercial therapies and a robust clinical and preclinical pipeline, underscoring its leadership in the biotechnology sector.
- Strategic Goals: BioMarin aims to unleash the potential of genetic science through a distinctive approach to drug discovery and development, targeting category-defining medicines that profoundly impact patients' lives, thereby strengthening its market position.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on BMRN
Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.35 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
14 Buy
5 Hold
0 Sell
Moderate Buy
Current: 56.990
Low
60.00
Averages
87.35
High
120.00
Current: 56.990
Low
60.00
Averages
87.35
High
120.00
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
- FDA Drug Approval: On January 13, 2026, Sentynl Therapeutics' Zycubo received FDA approval as the first treatment for pediatric patients with Menkes disease, representing a significant breakthrough in the treatment of rare neurodegenerative disorders and is expected to enhance patient quality of life.
- Food Labeling Reform: On January 21, 2026, the U.S. regulator issued a Request for Information aimed at improving gluten ingredient disclosure in foods, particularly focusing on allergic reactions to rye and barley, which could drive significant changes in food industry labeling transparency.
- Future Review Outlook: As February 2026 approaches, several drugs are set for FDA review, with the industry eagerly anticipating the regulatory outcomes, as successful approvals could present substantial market opportunities for related biotech firms.
- Biotech Stock Focus: The FDA's review decisions will directly impact the performance of biotech stocks, prompting investors to closely monitor the upcoming review results to assess market dynamics and investment strategies.
Continue Reading
BioMarin Plans $850M Senior Unsecured Notes Offering
- Financing Plan: BioMarin has outlined an $850M offering of senior unsecured notes due 2034, aimed at supporting its upcoming acquisition, reflecting the company's proactive fundraising strategy in the capital markets.
- Loan Arrangements: The company also announced a new $2B senior secured term loan 'B' facility, alongside an $800M senior secured term loan 'A' facility and a $600M senior secured revolving credit facility, ensuring ample liquidity for the acquisition.
- Acquisition Deal: BioMarin has agreed to acquire rare disease drug developer Amicus Therapeutics for nearly $4.8B in an all-cash transaction, marking a strategic expansion in the rare disease sector that is expected to enhance its product portfolio and market competitiveness.
- Expense Management: The company plans to borrow up to $150M under the new revolving credit facility to cover acquisition-related fees and expenses, ensuring liquidity and smooth execution of the acquisition.
Continue Reading